Toni Choueiri, MD· @DrChoueiri · X·· 1 天前评分70
正文 · 原文
Promising data presented by @AndreaNecchi at #ESMO26 #GDFather-NEO.
Nivo + Visugromab
• Higher response (pCR and ORR)
• At median F/U 15.7 mo: no recurrence observed after pCR
• No new safety signal
Paper out in @NatureMedicine. Congrats Andrea and co-authors !
@myESMO @OncoAlert
54 浏览 · 1 赞 · 1 转发 · 0 回复
会议摘要
4757RO按 Rapid oral 1: Genitourinary tumours, renal and urothelial 对上
Final pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab ± visugromab in MIBC (GDFather-NEO)
https://esmocongress.esmo.org来源：Toni Choueiri, MD · x.com